Study #2023-0963
HERTHENA-PanTumor01 (U31402-277): A phase 2, multicenter, multicohort, open-label, proof of concept study of Patritumab Deruxtecan (her3-dxd; u3-1402) in subjects with locally advanced or metastatic solid tumors.
MD Anderson Study Status
Enrolling
Treatment Agent
HER3-DXd
Description
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), and HER2-negative gastric cancerovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
Study phase:
Phase II
Physician name:
Funda Meric-Bernstam
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-923-4997
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.